Sign in

CIK 0001785279

  • Emerging growth company

Metagenomi Therapeutics, Inc.

Sign in to watch
Ticker
MGX
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
FY end
Dec 31
Entity type
Operating
EIN
813909017
Phone
+1 510-871-4880
Business address
5959 HORTON STREET, 7TH FLOOR, EMERYVILLE, CA, 94608
Former names
Metagenomi, Inc., Metagenomi Technologies, LLC
  1. 4 Open-market sale Chief Executive Officer sold 1,602 shares at $1.77 ($2,839)
  2. 4 Open-market sale Director sold 2,701 shares at $1.81 ($4,889)
  3. 4 Open-market sale Chief Financial Officer sold 1,576 shares at $1.81 ($2,853)
  4. 4 Open-market sale Chief Executive Officer sold 1,602 shares at $1.81 ($2,900)
  5. 4 Open-market sale Wein Matthew sold 199 shares at $1.81 ($360)
  6. 4 Derivatives Options or other derivatives
  7. 3 Insider Initial Statement of Ownership
  8. 4 Derivatives Options or other derivatives
  9. 4 Derivatives Options or other derivatives
  10. 4 Derivatives Options or other derivatives
  11. 4 Open-market sale Wein Matthew sold 199 shares at $1.75 ($348)
  12. 4 Open-market sale Chief Medical Officer sold 5,239 shares at $1.75 ($9,168)
  13. 4 Open-market sale Chief Financial Officer sold 1,576 shares at $1.75 ($2,758)
  14. 4 Open-market sale Chief Executive Officer sold 10,785 shares at $1.75 ($18,874)
  15. 4 Open-market sale Irish Jian sold 6,390 shares at $1.75 ($11,183)
  16. 4 Grant or award Chief Financial Officer acquired 14,000 shares (grant or award)
  17. 4 Grant or award Chief Executive Officer acquired 32,000 shares (grant or award)
  18. 4 Grant or award Irish Jian acquired 23,000 shares (grant or award)
  19. 4 Grant or award Wein Matthew acquired 7,425 shares (grant or award)
  20. 4 Grant or award Chief Medical Officer acquired 14,000 shares (grant or award)

Page 2 of 4 · 73 filings